GLP-1s Don’t Raise DTC Recurrence Risk, Study Says

Patients with differentiated thyroid cancer treated with the GLP-1s showed no increased risk of recurrence over a more than 5-year follow-up. Medscape Medical News

Read the full article on medscape.com